Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Lorenz, Felix K M ^a   Wilde, Susanne ^b   Voigt, Katrin ^a   Kieback, Elisa ^c   Mosetter, Barbara ^b   Schendel, Dolores J ^b   Uckert, Wolfgang ^a,c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; T LYMPHOCYTE RECEPTOR; CODON; PROTEIN E7;

ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL CLONE; CELLULAR IMMUNITY; CODON; CONTROLLED STUDY; DENDRITIC CELL; E7 ONCOGENE; EXPERIMENTAL STUDY; GENE MAPPING; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ISOLATION; STOP CODON; T LYMPHOCYTE RECEPTOR GENE; TARGET CELL; TRANSGENE; VIRUS CELL INTERACTION; VIRUS ONCOGENE; WILD TYPE; CELL CULTURE; CHEMISTRY; EPITOPE MAPPING; GENE THERAPY; GENETICS; IMMUNOLOGY; PAPILLOMAVIRIDAE; PHYSIOLOGY; PROCEDURES;

HUMAN PAPILLOMAVIRUS;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CODON; EPITOPE MAPPING; GENETIC THERAPY; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS;

EID: 84925711178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0121633     Document Type: Article

References (51)

1. Zuckerkandl E, Pauling L. Molecules as documents of evolutionary history. J Theor Biol. 1965 Mar; 8 (2):357-66. PMID: 5876245
2. Plotkin JB, Kudla G. Synonymous but not the same: the causes and consequences of codon bias. Nat Rev Genet. Nature Publishing Group; 2011 Jan; 12(1):32-42. doi: 10.1038/nrg2899 PMID: 21102527
3. Fath S, Bauer AP, Liss M, Spriestersbach A, Maertens B, Hahn P, et al. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One. 2011 Jan; 6(3):e17596. doi: 10.1371/journal.pone.0017596 PMID: 21408612
4. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B. N Engl J Med. 2011; 365(25).
5. Carbonaro DA, Zhang L, Jin X, Montiel-equihua C, Geiger S, Cooper A, et al. Preclinical Demonstration of Lentiviral Vector-mediated Correction of Immunological and Metabolic Abnormalities in Models of Adenosine Deaminase Deficiency. Mol Ther. 2014; 22(3):607-22. doi: 10.1038/mt.2013.265 PMID: 24256635
6. Huston MW, van Til NP, Visser TP, Arshad S, Brugman MH, Cattoglio C, et al. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol Ther. Nature Publishing Group; 2011 Oct; 19(10):1867-77. doi: 10.1038/mt.2011.127 PMID: 21750532
7. Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, et al. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One. 2012 Jan; 7(5):e37671. doi: 10.1371/journal.pone.0037671 PMID: 22655063
8. Shiver JW, Fu T, Chen L, Casimiro DR, Davies M, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(January): 331-5. PMID: 11797011
9. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther. 2009 Apr; 17(4):585-92. doi: 10.1038/mt.2009.5 PMID: 19223870
10. Wang S, Hackett A, Jia N, Zhang C, Zhang L, Parker C, et al. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One. 2011 Jan; 6(12):e28757. doi: 10.1371/journal.pone.0028757 PMID: 22205966
11. Kwak K, Jiang R, Jagu S, Wang JW, Wang C, Christensen ND, et al. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation. PLoS One. 2013 Jan; 8(3):e60507. doi: 10.1371/journal.pone.0060507 PMID: 23536912
12. Deml L, Bojak A, Steck S, Wild J, Schirmbeck R, Wolf H, et al. Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virus Type 1 Gag Protein. J Virol. 2001; 75(22).
13. Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel AMT, Corthals J. Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Mol Ther Acid. 2013; 1(August):1-9.
14. Li C, Goudy K, Hirsch M, Asokan A, Fan Y, Alexander J, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci. 2009 Jun 30; 106(26):10770-4. doi: 10.1073/pnas.0902269106 PMID: 19541644
15. Ho O, Green WR. Alternative Translational Products and Cryptic T Cell Epitopes: Expecting the Unexpected. J Immunol. 2006 Dec 1; 177(12):8283-9. PMID: 17142722
16. Zur Hausen H. Condylomata Acuminata and Human Genital Cancer. Cancer Res. 1976; 36:794. PMID: 175942
17. Walboomers JM, JacobsM V, Manos MM, Bosch FX, Kummer JA, Shah K V, et al. Human Papillomavirus is a Necessary Cause of Invasive Cervical Cancer Worldwide. J Pathol. 1999;(May):12-9.
18. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009 Sep; 15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737 PMID: 19723653
19. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy Against HPV16/ 18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses. Sci Transl Med. 2012 Oct 10; 4 (155). doi: 10.1126/scitranslmed.3004414 PMID: 23052295
20. Tindle R. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002; 2(January):1-7.
21. Gan L, Jia R, Zhou L, Guo J, Fan M. Fusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine. PLoS One. 2014 Jan; 9(9):e108892. doi: 10.1371/journal.pone.0108892 PMID: 25265018
22. Lin C-T, Tsai Y-C, He L, Calizo R, Chou H-H, Chang T-C, et al. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. J Biomed Sci. 2006 Jul; 13(4):481-8. PMID: 16649071
23. Cid-Arregui A, Juarez V, zur Hausen H. A Synthetic E7 Gene of Human Papillomavirus Type 16 That Yields Enhanced Expression of the Protein in Mammalian Cells and Is Useful for DNA Immunization Studies. J Virol. 2003; 77(8).
24. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975 Mar; 45(3):321-34. PMID: 163658
25. Wilde S, Sommermeyer D, Frankenberger B, Schiemann M, Milosevic S, Spranger S, et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood. 2009 Sep; 114(10):2131-9. doi: 10.1182/blood-2009-03-209387 PMID: 19587379
26. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007 Jul 1; 110(1):201-10. PMID: 17371945
27. Leisegang M, Engels B, Meyerhuber P, Kieback E, Sommermeyer D, Xue S-A, et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med. Springer-Verlag; 2008; 86(5):573-83. doi: 10.1007/s00109-008-0317-3 PMID: 18335188
28. Engels B, Cam H, Schüler T, Indraccolo S, Gladow M, Baum C, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. 2003 Aug 10; 14(12):1155-68. PMID: 12908967
29. Britten CM, Meyer RG, Kreer T, Drexler I, Wolfel T, Herr W. The use of HLA-A. 0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-g ELISPOT assays. J Immunol Methods. 2002; 259:95-110. PMID: 11730845
30. Suhoski MM, Golovina TN, Aqui NA, Tai VC, Varela-rohena A, Milone MC, et al. Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules. Mol Ther. 2007; 15 (5):981-8. PMID: 17375070
31. Kammertoens T, Blankenstein T. It's the Peptide-MHC Affinity, Stupid. Cancer Cell. Elsevier; 2013 Apr 15; 23(4):429-31. doi: 10.1016/j.ccr.2013.04.004 PMID: 23597560
32. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, et al. Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity. Cancer Cell. Elsevier Inc.; 2013 Apr 15; 23(4):516-26. doi: 10.1016/j.ccr.2013.03.018 PMID: 23597565
33. Starck SR, Shastri N. Non-conventional sources of peptides presented by MHC class I. Cell Mol Life Sci. 2011;1471-9.
34. Lee S, Liu B, Lee S, Huang S, Shen B, Qian S. Global mapping of translation initiation sites in mammalian cells at single-nucleotide resolution. Proc Natl Acad Sci. 2012; 109(37).
35. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and-B locus protein of known sequence. PLoS One. 2007 Jan; 2(8):e796. PMID: 17726526
36. Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A. 2001 Nov 6; 98(23):13255-60. PMID: 11687624
37. Yewdell JW, Antón LC, Bennink JR. Defective Ribosomal Products (DRiPs)-A Major Source of Antigenic Peptides for MHC Class I Molecules? J Immunol. 1996; 157:1823-6. PMID: 8757297
38. Bullock BTNJ, Eisenlohr LC. Ribosomal Scanning Past the Primary Initiation Codon as a Mechanism for Expression of CTL Epitopes Encoded in Alternative Reading Frames. J Exp Med. 1996; 184 (October).
39. Bruce AG, Atkins JF, Gesteland RF. tRNA anticodon replacement experiments show that ribosomal frameshifting can be caused by doublet decoding. Proc Natl Acad Sci. 1986 Jul; 83(14):5062-6. PMID: 2425361
40. Jardetzky T, Lane W, Robinson R, Madden D, Wiley D. Identification of self peptides bound to purified HLA-B27. Nature. 1991; 353:326. PMID: 1922338
41. Gurunathan S, Klinman DM, Seder R a. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol. 2000 Jan; 18:927-74. PMID: 10837079
42. Kedl RM, ReesWa, Hildeman DA, Schaefer B, Mitchell T, Kappler J, et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med. 2000; 192(8):1105-13. PMID: 11034600
43. Seedorf K, Krämmer G, Durst M, Suhai S, Röwekamp WG. Human Papillomavirus Type 16 DNA Sequence. Virology. 1985; 145:181-5. PMID: 2990099
44. Javorovic M, Wilde S, Zobywalski A, Noessner E, Lennerz V, Wölfel T, et al. Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells. J Immunother. 2008 Jan; 31 (1):52-62. PMID: 18157012
45. Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C. Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med. 2010 Jan; 8:90. doi: 10.1186/1479-5876-8-90 PMID: 20920165
46. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, UckertW, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest. 2010; 120(11):3869-77. doi: 10.1172/JCI43437 PMID: 20978348
47. Steinle A, Reinhardt C, Jantzer P, Schendel DJ. In vivo expansion of HLA-B35 alloreactive T cells sharing homologous T cell receptors: evidence for maintenance of an oligoclonally dominated allospecificity by persistent stimulation with an autologous MHC/peptide complex. J Exp Med. 1995 Feb 1; 181 (2):503-13. PMID: 7836907
48. Brochet X, Lefranc M-P, Giudicelli V. IMGT / V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008; 36:503-8.
49. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA. Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 Stability. Cancer Res. 2006; 66:8878-86. PMID: 16951205
50. Scholten KBJ, Kramer D, Kueter EWM, Graf M, Schoedl T, Meijer CJLM, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol. 2006 May; 119(2):135-45. PMID: 16458072
51. Kieback E, Charo J, Sommermeyer D, Blankenstein T, Uckert W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc Natl Acad Sci. 2008 Jan 15; 105 (2):623-8. doi: 10.1073/pnas.0710198105 PMID: 18182487